Overview

A Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1b Infection

Status:
Completed

Trial end date:
2016-10-26

Target enrollment:

Participant gender:

Summary

A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination with Peg-interferon and Ribavirin in Treatment Naïve East Asian Subjects with Chronic Hepatitis C Virus Genotype 1b Infection.

Phase:

Phase 2

Details

Lead Sponsor:

TaiGen Biotechnology Co., Ltd.

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Ribavirin